We have shown that the percentage of immunophenotypic CD34+CD38−CD123+ leukemic stem cells (iLSCs) at diagnosis has a significant impact on complete response and survival in younger AML patients treated by intensive chemotherapy [10]. The gene discussed is CD34; the disease is acute myeloid leukemia.